Aller au contenu

Bonus Episode: Psychedelic Research Inside an Academic Medical Center with Scott Thompson, PhD

27 octobre 2026 · 1 h 12 min

Notes de l’épisode

In this bonus episode, Dr. Ben Everett speaks with Scott Thompson, PhD, professor of psychiatry at the University of Colorado School of Medicine, where he directs the Novel Therapeutics in the Brain and Behavior Innovation Center and leads the Psychedelic Public Policy Partnership. Drawing on more than 40 years of synaptic research, Dr. Thompson describes how an unexpected finding on SSRI action led his lab to show in mice that psilocybin's antidepressant-like effects persisted even when the 5-HT2A receptor was blocked, and what that finding means for the question of whether the psychedelic experience itself is the medicine.

As psychedelic compounds advance through late-stage development, clinicians face open questions about mechanism, trial design, safety, and access. This conversation covers functional unblinding and the search for objective endpoints such as anhedonia, what it takes to run Schedule I research inside an academic medical center, and real-world outcome and safety data from more than 2,300 people who received regulated psilocybin services in Colorado and Oregon. Dr. Thompson also discusses the role of psychotherapy, the evidence on microdosing, and phase III programs including Definium's DT120 LSD formulation and Beckley Atai's intranasal 5-MeO-DMT.

KEY EPISODE HIGHLIGHTS: A SUPERCHARGED SSRI [45:30]

“psychedelics do what SSRIs do. They just do it more potently and more quickly.”

Dr. Thompson's working hypothesis frames psychedelics as faster, stronger versions of a mechanism clinicians already use every day, which shapes how his lab tests whether the trip is required.

A DOSE CEILING IN REAL-WORLD DATA [27:31]

“people who got doses of psilocybin less than thirty milligrams displayed the same improvement in symptoms as people who got doses more than thirty-five”

Outcome data from more than 2,300 regulated psilocybin clients suggest a threshold rather than a linear dose-response, challenging the assumption that higher doses yield greater benefit.

MICRODOSING AND EXPECTANCY [31:00]

“There's strong evidence now that microdosing is primarily a placebo effect.”

Placebo-controlled studies show benefit tracks what participants believed they received rather than what they actually took, useful context when patients ask about microdosing.

CHAPTERS:

00:00 – Introduction: Is the Experience the Medicine?

02:00 – From Basel and Zurich to Psilocybin and Synaptic Plasticity

07:30 – Psychedelic Research and Policy at CU Anschutz

10:30 – Functional Unblinding and the Search for Objective Endpoints

15:00 – Facilitator Support, Placebo Response, and Predictive Biomarkers

20:00 – Building Safety Into Colorado's Regulated Psilocybin Services

24:30 – Real-World Outcomes From Colorado and Oregon Psilocybin Clients

28:00 – Dose Thresholds, MEQ-30 Scores, and the Evidence on Microdosing

32:00 – Running Schedule I Research: Regulation, Funding, and INDs

36:30 – Safety Signals: Psychosis, Suicidality, and Adverse Event Follow-Up

43:00 – Blocking the 5-HT2A Receptor: Is the Trip Necessary?

47:30 – Cost, Access, and Shorter-Acting Psychedelics

50:30 – Receptor Promiscuity and Non-Hallucinogenic Compounds

53:30 – The Role of Psychotherapy in Psychedelic Treatment

59:30 – Definium's DT120: Phase III Data, Payer Realities, and Dose Selection

01:07:00 – Beckley Atai's 5-MeO-DMT and Other Short-Acting Compounds

01:09:30 – Clinical Takeaways

LINKS:

Full transcript and show notes:

https://www.psychiatrist.com/jcp/ep27-psychedelic-research-academic-medical-center-scott-thompson/

Journal of Clinical Psychiatry

https://www.psychiatrist.com/jcp/

Publisher of peer-reviewed research discussed in this episode.

Dr. Scott Thompson – LinkedIn

https://www.linkedin.com/in/scott-thompson-241a1a15/

Harnessing Psilocybin (Hesselgrave et al., PNAS, 2021)

https://doi.org/10.1073/pnas.2022489118

Dr. Thompson's mouse study showing psilocybin's antidepressant-like effects persisted despite 5-HT2A receptor blockade.

Colorado Natural Medicine Program

https://dpo.colorado.gov/NaturalMedicine

State program for regulated psilocybin services discussed in this episode.

Definium Therapeutics

https://definiumtx.com

Developer of DT120, the LSD formulation with phase III results in MDD and GAD.

#Psilocybin #PsychedelicMedicine #LSD #Neuroplasticity #FunctionalUnblinding

Tous les épisodes de The Journal of Clinical Psychiatry Podcast

Paramètres

Affichage

Langue

Détermine les stations affichées en premier sur la page d’accueil.

Historique

Les stations et épisodes écoutés récemment et tes dernières recherches sont seulement enregistrés dans ce navigateur.

Notifications

Un court message quand un podcast que tu suis publie un nouvel épisode. Désactive un podcast précis avec la cloche sur sa page.

Compte

Enregistrez vos favoris – dans l’app et sur le site.

Raccourcis clavier

/
Ouvrir la recherche
Espace
Lecture ou pause
← →
Dans le lecteur : 15 s en arrière, 30 s en avant (épisodes) · dans une rangée : tuile suivante
↑ ↓
Dans une rangée : cible dans la tuile
Début / Fin
Dans une rangée : première ou dernière tuile
Esc
Fermer la fenêtre ou le menu
?
Cet aperçu
En cours de lecture

Voir la station

À suivre

    Ajoutez des épisodes avec « À suivre » – ils seront lus après l'épisode en cours.